Martine Kallemeijn

Glofitamab plus gemcitabine and oxaliplatin (GemOx) versus rituximab-GemOx for relapsed or refractory diffuse large B-cell lymphoma (STARGLO): a global phase 3, randomised, open-label trial

Jeremy S. Abramson, Matthew Ku, Mark P. Hertzberg et al. · The Lancet · 2024 · 114 citations

Hematological Malignancy, Open-label Trial, Lymphoid Neoplasia +8

Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells

Martine Kallemeijn, Anne Mieke H. Boots, Michèle Y. van der Klift et al. · Scientific Reports · 2017 · 49 citations · Full text

Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging

Martine Kallemeijn, François G. Kavelaars, Michèle Y. van der Klift et al. · Frontiers in Immunology · 2018 · 34 citations · Full text

The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age

Alice F. Muggen, Madelon M.E. de Jong, Ingrid L. M. Wolvers‐Tettero et al. · Immunity & Ageing · 2019 · 31 citations · Full text

Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia

Martine Kallemeijn, Dick de Ridder, Joyce Schilperoord‐Vermeulen et al. · PLoS ONE · 2017 · 11 citations · Full text

Apoptosis Impact, Lymphocyte Development, Adaptive Immune System +28